BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene …

-If successful, BridgeBio’s investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body’s hormone and steroid balance by enabling people with CAH to make their